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MicronucleiPurpose: To investigate whether rotational techniques (Volumetric Modulated Arc Therapy – VMAT) are
associated with a higher risk for secondary primary malignancies compared to step-and-shoot Intensity
Modulated Radiation Therapy (ss-IMRT). To this end, radiation therapy (RT) induced DNA double-strand-
breaks and the resulting chromosomal damage were assessed in peripheral blood T-lymphocytes of pros-
tate cancer (PCa) patients applying cH2AX foci and G0 micronucleus (MN) assays.
Methods and materials: The study comprised 33 PCa patients. A blood sample was taken before start of
therapy and after the 1st and 3rd RT fraction to determine respectively the RT-induced cH2AX foci
and MN. The equivalent total body dose (DETB) was calculated based on treatment planning data.
Results: A linear dose response was obtained for cH2AX foci yields versus DETB while MN showed a lin-
ear-quadratic dose response. Patients treated with large volume (LV) VMAT show a signiﬁcantly higher
level of induced cH2AX foci and MN compared to IMRT and small volume (SV) VMAT (p < 0.01). Assuming
a linear-quadratic relationship, a satisfactory correlation was found between both endpoints (R2 0.86).
Conclusions: Biomarker responses were governed by dose and irradiated volume of normal tissues. No
signiﬁcant differences between IMRT and rotational therapy inherent to the technique itself were
observed.
 2013 The Authors. Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 107 (2013)
377–381Radiation therapy (RT) is a cornerstone of cancer management
[1]. However, Hall and Wuu stated that ‘‘radiation is a two-edged
sword: it is the major modality to treat cancer, but it can also be
the cause of cancer’’ [2]. As contemporary techniques are able to
deliver higher doses more precisely (‘image-guided radiotherapy’
(IGRT)), the therapeutic ratio of RT increases. Consequently, the
cure rates increase and the issue of the development of radiation
induced secondary malignancies (RISM) becomes more important
[3,4].
Compared to 3D conformal RT (3DCRT) IMRT is hypothesised to
increase the risk for RISM because it requires more radiation ﬁelds
involving a larger volume of normal tissue exposed to low radia-
tion doses and because it requires more monitor units (MU) to de-
liver a speciﬁed dose causing a larger total body dose due to head
leakage and collimator scatter [2,3,5]. Using Volumetric Modulated
Arc Therapy (VMAT), dose rate, shape of the beam and speed ofrotation can be changed during gantry rotation enabling to give
the RT fraction in one single rotation. Variations on the VMAT prin-
ciple are RapidArc (Varian Medical Systems, Inc., Palo Alto, CA,
USA) and IMAT (Intensity Modulated Arc Therapy) [6]. No informa-
tion is available regarding RISM following arc therapy.
In this paper, a biomarker approach is applied to compare the
potential risk for radiation induced RISM in prostate cancer (PCa)
patients treated with ss-IMRT and VMAT (small volume and high
volume). To this end RT induced DNA double-strand-breaks
(cH2AX foci) and the resulting chromosomal damage (MN) were
assessed in PBLs.Materials and methods
Patient population and blood sampling
The study population consisted of 33 PCa patients treated at the
Department of Radiation Oncology (Ghent University Hospital, Bel-
gium) between October 2010 and August 2011. Heparinised blood
samples were obtained from patients treated with 3 different RT
modalities: (1) ss-IMRT (Elekta Synergy linear accelerator)
(n = 12), (2) small volume (SV) VMAT (RapidArc; Varian Clinac
linear accelerator) (n = 9) and (3) large volume (LV) VMAT (IMAT;
Table 1
Overview of patient population and treatment modalities considered in this study.
RT technique Age MU/fraction Photon energy (MV) PTV Dose/fraction Total tumour dose
(dm3) (Gy) (Gy)
IMRT Mean 61.6 328.9 6 0.136 2.09 78.03
Range 47.5–72.2 305–379 0.086–0.160 1.92–2.25 69.12–85.50
SV-VMAT Mean 64.9 378.8 6 0.137 2.02 75.58
Range 50.8–77.3 322–468 0.062–0.211 2.00–2.10 72.00–77.67
LV-VMAT Mean 64.8 428.1 18 0.231 1.83 65.22
Normofractionation Range 57.6–73.5 275–734 0.083–1.048 1.27–2.09 45.00–75.90
LV-VMAT Mean 67.7 733.8 18 0.17 2.85 71.19
Hypofractionation Range 60.5–77.3 532–1064 0.138–0.203 2.83–2.87 70.75–71.75
Abbreviations: MU, number of monitor units; MV, mega voltage; PTV, planned target volume; Gy, gray.
378 Early biomarkers for secondary primary cancer following radiation therapyElekta SL18 linear accelerator). The latter population was further
subdivided in a group receiving normofractionation (n = 8) and a
group receiving hypofractionation (n = 4). In these groups the dose
per fraction was respectively 2.09, 2.02, 1.83 and 2.85 Gy. Details
regarding patient population and treatment modalities are sum-
marised in Table 1. Before each fraction, imaging was applied to
verify position of patient and ﬁelds: Electronic Portal Imaging De-
vice (EPID) for LV-VMAT and Cone Beam Computed Tomography
(CBCT) for ss-IMRT and SV-VMAT. After obtaining signed informed
consent, blood samples were taken at different time points, as
shown in Fig. 1. Blood samples taken a few minutes after exposure
reﬂect the average dose given to the lymphocyte pool in the
peripheral blood [7]. Blood sampling for the cH2AX foci was per-
formed before and after the ﬁrst fraction, blood sampling for the
MN assay was performed before and after the third fraction. In pre-
vious work it was shown that the number of radiation induced MN
is proportional to the equivalent total body dose (DETB) up to three
fractions of RT treatment [8].cH2AX foci and G0 MN assays
The procedure for the cH2AX foci assay on T-lymphocytes is de-
scribed in detail in a previous paper [9]. The Metacyte software
module of the Metafer 4 scanning system (MetaSystems, Altluss-
heim, Germany) was applied for automated scanning of the slides,
for spot detection and foci scoring [10].
The procedure for the G0 MN assay can be found elsewhere [11].
The MSearch software module of the Metafer 4 scanning system
(MetaSystems) was applied for automated scanning of binucleated
(BN) cells and scoring of MN. Gallery images of the positive as well
as the negative class of BN cells were checked and scores were ad-
justed when necessary.In vitro irradiations
For the determination of the cH2AX foci and MN in vitro dose
response curves, whole blood samples of 3 healthy donors were ex-
posed to different doses up to 500 mGy of Co-60 c-rays. The same
procedures as used for the patient samples were applied.Blo
BEFORE 1st RT fraction
Control sample foci assay Control sample MN assay
Fig. 1. Time schedule of the bloCalculation of the equivalent total body dose
The equivalent total body dose DETB was calculated for each pa-
tient based on the treatment planning data. To this end the mean
dose within the skin contour of the scanned volume was norma-
lised to the patient mass. For the cH2AX foci assay DETB has to be
interpreted as the equivalent total body blood dose. As liver,
heart/large blood vessels and lungs contain together 38.5% of the
total blood volume it was assumed that 61.5% of the blood pool
is distributed uniformly over the rest of the body. In the DETB cal-
culation the contribution of the medical imaging, CBCT and EPID
was also taken into account.Statistical analysis
Statistical analysis of the data was performed using the Statisti-
cal Package for Social Sciences (SPSS) version 20.0. The 2-tailed
Mann–Whitney test was performed to investigate the signiﬁcance
of differences in biomarker scores. The statistical power of the ob-
tained results was assessed using G⁄Power version 3.1.4 software
[12].
Results
cH2AX foci and MN induced in vivo by different RT modalities for
prostate cancer
Fig. 2 represents the number of radiation induced (background
corrected) cH2AX foci/T-lymphocyte plotted against DETB after one
RT fraction for each patient. Taking into account all foci data, the
number of cH2AX foci increases linearly with DETB but with a rel-
atively large scatter of the data (R2 0.67). For the IMRT patient
group two separated clouds of data points can be noticed in the
dose ranges 0–20 mGy and 40–60 mGy. Compared to the in vitro
dose response patient foci-DETB data are generally higher, espe-
cially for the hypofractionated LV-VMAT. However, differences
are not statistically signiﬁcant (p 0.12).
The mean values of DETB/fraction and number of radiation in-
duced cH2AX foci averaged over the patients for each RT technique
applied are summarised in Table 2 and represented graphically in
Fig. 2 by the  symbols with standard deviations as error bars. Theod sampling 
AFTER 1st RT fraction
(within 30 min/ end of RT)
AFTER 3rd RT fraction 
Test sample foci assay Test sample MN assay 
od samplings of the study.
Fig. 2. cH2AX foci/T-lymphocyte induced (background corrected) by the ﬁrst fraction of RT as a function of DETB. The full line represents a linear ﬁt to all in vivo data (R2 0.67).
The open circles represent the number of cH2AX foci/T-lymphocyte after in vitro irradiation of whole blood. The dashed line represents the linear regression through the
in vitro data points.
Table 2
Mean values of DETB after 1 and 3 fractions, mean number of radiation induced cH2AX foci and mean number of radiation-induced MN/1000BN averaged over the patients for
each RT technique applied.
DETB/fraction (mGy) cH2AX foci/T-lymphocyte DETB/3 fractions (mGy) MN/1000BN
Mean (SD) Range (mGy) Mean (SD) Range Mean (SD) Range Mean (SD) Range
IMRTa 36.06 (20.11) 9.14–63.13 0.36 0.18–0.59 87.34 (53.27) 34.80–176.69 2 5 to 10
CBCT 3.93 19.17
Low volume arc therapya 31.18 (7.03) 18.83–37.77 0.22 0.09–0.47 96.26 (21.11) 61.70–128.61 7 1 to 14
CBCT 2.77 13.51
High volume arc therapya (Normofractionation) 72.92 (19.61) 55.19–104.48 0.83 0.39–1.19 225.07 (58.82) 171.88–319.73 26 8–64
EPID 5.2 21.9
High volume arc therapya (Hypofractionation) 106.59 (11.09) 92.74–116.09 1.39 1.27–1.59 326.09 (33.27) 284.53–354.56 53 41–65
Abbreviations: DETB, equivalent total body dose; CBCT, Cone Beam Computed Tomography; EPID, Electronic Portal Imaging Device.
a Including the CBCT/EPID dose contribution.
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compared to SV VMAT which is in line with the DETB values (p
0.039). On the other hand the mean number of foci induced by
LV-VMAT was signiﬁcantly higher compared to both IMRT and
SV-VMAT (p < 0.001). Signiﬁcance remains even when the LV-
VMAT patients are subdivided according to the normo- and hypo-
fractionation regime (0.001 < p < 0.005). The same trend is seen for
the DETB values. The statistical signiﬁcance of differences in foci
numbers obtained among these rather small patient populations
was supported by a post hoc power analysis which indicated a very
good power (range 0.916–0.999) except for the comparison be-
tween IMRT and SV-VMAT (0.512).
In Fig. 3 the number of MN/1000BN induced in patients’ PBLs
are plotted versus DETB after the 3rd fraction for all patients. The
number of radiation induced MN (background corrected) shows a
linear-quadratic response as a function of the calculated DETB (R2
0.64). In vitro irradiation of whole blood clearly results in lower
MN yields than observed for the RT patients and calculated DETB.
This difference in MN dose response is signiﬁcantly different (p
0.021). The mean number of radiation-induced MN/1000BN andmean DETB after the 3rd fraction of RT averaged over patients for
the different modalities are also given in Table 2 and represented
by the  symbols in Fig. 3. LV-VMAT results in signiﬁcantly higher
values compared to both IMRT and SV-VMAT (p < 0.001). The
signiﬁcance of the difference holds when the LV-VMAT group is
subdivided according to normo- and hypofractionation schedule.
LV-VMAT hypofractionation (mean tumour dose per fraction of
2.85 Gy) even showed twice as much MN formation as normofrac-
tionation (mean tumour dose per fraction of 1.83 Gy).MN versus cH2AX foci
The correlation between the number of radiation induced
(background corrected) MN/1000BN and cH2AX foci/1000 T-lym-
phocytes for the patient population is represented in Fig. 4. A lin-
ear-quadratic relationship between both biomarkers of radiation
damage results in an excellent ﬁt (R2 0.86). The mean baseline level
of the cH2AX foci was 0.15 ± 0.14 and for the MN was 17.45 ± 5.82.
No correlation between the baseline levels of both biomarkers
could be demonstrated (R2 0.07).
Fig. 3. Radiotherapy induced (background corrected) MN per 1000 binucleated cells (MN/1000BN) after the third fraction as a function of DETB. The full line represents a
linear-quadratic ﬁt to all data points (R2 0.64). The open circles represent the number of MN/1000BN after in vitro irradiation of whole blood. The dashed line represents the
linear-quadratic ﬁt through the in vitro data points.
Fig. 4. Radiotherapy induced (background corrected) MN expressed as MN/1000BN after the 3rd fraction as a function of the number of radiotherapy-induced (background
corrected) foci per 1000 T-lymphocytes after the 1st fraction. The full line represents a linear-quadratic ﬁt through the in vivo data points (R2 0.86). The dashed line represents
a linear-quadratic ﬁt through the in vitro data points (R2 0.97).
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In present study, a biomarker approach was used to compare
the risk for development of RISM in PCa patients receiving ss-IMRT,
SV-VMAT and LV-VMAT in a normo- and hypofractionation regime.The patients’ cH2AX foci and MN data show in general a system-
atic increase with DETB. Foci yields were borderline signiﬁcantly
higher in IMRT compared to SV-VMAT treated patients but in line
with the DETB values. It is often stated that SV-VMAT reduces the
daily treatment time compared to IMRT resulting in a smaller
J. Werbrouck et al. / Radiotherapy and Oncology 107 (2013) 377–381 381amount of scatter radiation from the treatment head, which should
lower the risk of RISM [13]. On the other hand Aznar et al. indi-
cated that the mean dose to healthy tissues was slightly increased
for SV-VMAT treatment compared to 5-ﬁeld IMRT [13,14]. Our data
do not indicate a signiﬁcant difference in risk of RISM inherent to
the technique itself.
For IMRT treated patients, receiving a DETB/fraction less than
20 mGy, the number of observed cH2AX foci was 3–5 higher than
expected from the in vitro dose–response. A comparison of the low
dose IMRT data with the in vivo dose response determined over the
total dose range resulted in a borderline signiﬁcant difference (p
0.046). Possible explanations are underestimation of DETB by low
dose radiation scatter and/or head leakage not included in the cal-
culation of DETB or the bystander effect [15,16]. Such an effect was
not observed for the micronuclei and also not for the in vitro irra-
diated samples.
A systematic comparison of in vivo and in vitro data shows high-
er scores for both biomarkers after in vivo exposure especially for
LV-VMAT produced by 18 MV X-rays. This difference may be ex-
plained by the factors just mentioned but for the LV-VMAT data
also photo-neutrons, which have a high RBE, may play a role [5].
The used biomarkers can also be considered as early biomarkers
of secondary cancer risk after RT. In a radiosensitive Patched-1
mouse model cH2AX foci induced in shielded cerebellum of mice
irradiated in vivo were linked to medulloblastoma formation
[17]. MN as marker for chromosomal damage are linked to carcino-
genesis due to the causal role of balanced chromosome rearrange-
ments in early stages of carcinogenesis and the increased MN
frequency seen in cancer patients [18].Conclusion
A comparative study of cH2AX foci and MN as radiation effect
biomarkers in PCa patient groups treated with IMRT and VMAT
(small and large volume) reveals that the biomarker response
was governed by dose and irradiated volume of normal tissue
However, no signiﬁcant differences between IMRT and rotational
therapy inherent to the technique itself were observed.Conﬂict of interest
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